Compare, Analyse Glenmark Pharma with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs TEVA PHARMA (Israel) - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GLENMARK PHARMA   TEVA PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
TEVA PHARMA
Dec-13
GLENMARK PHARMA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs7122,961-   
Low Rs4842,573-   
Sales per share (Unadj.) Rs349.61,699.6-  
Earnings per share (Unadj.) Rs32.8106.2-  
Cash flow per share (Unadj.) Rs44.3243.6-  
Dividends per share (Unadj.) Rs2.0092.94-  
Dividend yield (eoy) %0.33.4 10.0%  
Book value per share (Unadj.) Rs198.61,888.0-  
Shares outstanding (eoy) m282.17848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.71.6 105.0%   
Avg P/E ratio x18.226.1 69.9%  
P/CF ratio (eoy) x13.511.4 118.7%  
Price / Book Value ratio x3.01.5 205.3%  
Dividend payout %6.187.5 7.0%   
Avg Mkt Cap Rs m168,6252,346,458 7.2%   
No. of employees `00012.044.9 26.8%   
Total wages/salary Rs m20,5610-   
Avg. sales/employee Rs Th8,196.032,067.6 25.6%   
Avg. wages/employee Rs Th1,708.10-   
Avg. net profit/employee Rs Th768.52,003.2 38.4%   
INCOME DATA
Net Sales Rs m98,6551,441,278 6.8%  
Other income Rs m2,0810-   
Total revenues Rs m100,7361,441,278 7.0%   
Gross profit Rs m15,858394,695 4.0%  
Depreciation Rs m3,259116,500 2.8%   
Interest Rs m3,34628,309 11.8%   
Profit before tax Rs m11,335249,886 4.5%   
Minority Interest Rs m01,135 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,672-164,036 -1.0%   
Tax Rs m3,756-3,051 -123.1%   
Profit after tax Rs m9,25090,036 10.3%  
Gross profit margin %16.127.4 58.7%  
Effective tax rate %33.1-1.2 -2,714.5%   
Net profit margin %9.46.2 150.1%  
BALANCE SHEET DATA
Current assets Rs m66,968973,434 6.9%   
Current liabilities Rs m40,211848,917 4.7%   
Net working cap to sales %27.18.6 313.9%  
Current ratio x1.71.1 145.2%  
Inventory Days Days8391 91.8%  
Debtors Days Days8196 84.7%  
Net fixed assets Rs m33,322470,753 7.1%   
Share capital Rs m2823,548 8.0%   
"Free" reserves Rs m55,7700-   
Net worth Rs m56,0521,600,987 3.5%   
Long term debt Rs m35,738736,958 4.8%   
Total assets Rs m132,8883,293,783 4.0%  
Interest coverage x4.49.8 44.6%   
Debt to equity ratio x0.60.5 138.5%  
Sales to assets ratio x0.70.4 169.7%   
Return on assets %9.53.6 263.8%  
Return on equity %16.55.6 293.4%  
Return on capital %17.84.9 361.3%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m40,1400-   
CASH FLOW
From Operations Rs m13,242229,665 5.8%  
From Investments Rs m-6,990-81,380 8.6%  
From Financial Activity Rs m-7,387-275,499 2.7%  
Net Cashflow Rs m-2,971-127,213 2.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 70.95 Rs / USD

Compare GLENMARK PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare GLENMARK PHARMA With: FDC LTD.  BIOCON   WYETH LTD  DIVIS LABORATORIES  JUBILANT LIFE SCIENCES  



Today's Market

September Quarter Results, IPO Buzz, and Top Stocks in Action Today(Pre-Open)

On Wednesday, Indian share markets traded rangebound throughout the day and ended marginally higher. The BSE Sensex closed higher by 95 points to end above 39,000-mark.

Related Views On News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound (Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival (Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

5 Smart Money Stocks to Profit from the Market Rebound (The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

My Top 10 Stocks for Accelerated Profits

Oct 18, 2019

Equitymaster's co-head of research and editor of Microcap Millionaires, Rahul Shah, talks to us about his market-beating system and his 10 best stocks to buy now. Listen in...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Oct 23, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS